Wegovy and Ozempic may reduce arthritis inflammation directly. GLP-1 hormone found inside joints. - help needed

[GoldbergFan_X]

Researchers published on May 22 that the GLP-1 hormone targeted by weight loss drugs like Wegovy and semaglutide is present inside the joints of arthritis patients, not just in the metabolic and digestive systems where it was previously understood to act. The discovery suggests GLP-1 drugs may be reducing arthritis inflammation directly, separate from the weight loss effect that would otherwise reduce joint loading.

This is the second arthritis and GLP-1 finding this week, alongside the walking technique trial, adding to growing evidence that these drugs have anti-inflammatory effects beyond their well-documented metabolic actions.

260522041348www.sciencedaily.com

[Rough Reece]

GLP-1 receptors in joints was not expected and it changes how clinicians should be thinking about the arthritis improvements reported by patients on these drugs

[ClaudioHerrera]

Patients on semaglutide for weight loss reporting arthritis improvement have been attributed entirely to reduced mechanical load from weight loss. This suggests a separate direct anti-inflammatory mechanism

[PlanckLimit81]

The pharmacological implications are significant. If GLP-1 acts directly in joints you might be able to design joint-specific GLP-1 agonists that treat arthritis without the systemic weight loss effects

[AJStyles92]

The emerging picture of GLP-1 drugs is that they are doing far more than we understood when they were approved. Cardiovascular benefits, kidney protection, potential neuroprotection, and now direct joint effects

[Taker04]

Rheumatologists will want to know whether this means patients with inflammatory arthritis who are not obese might benefit from GLP-1 drugs. The current approval basis does not cover that indication

[Idle Mila]

The mechanism plausibility is there given that GLP-1 is known to have anti-inflammatory properties. Finding the receptor in joint tissue gives the mechanism a physical basis

[alwaysPatrick19]

This adds to the growing list of off-label or upcoming approved indications for semaglutide class drugs. The drug class is turning out to be remarkably broad in its physiological effects

[RomanReigns02]

Novo Nordisk and Eli Lilly will be watching this research very carefully. A new major indication for GLP-1 drugs in the largest joint disease population would be a significant commercial opportunity

[BlackMamba]

The week in which walking technique and GLP-1 both show arthritis benefits is a good week for the many millions of people living with knee osteoarthritis